Abstract
Under 262(l)(2)(A) of the Biologics Price Competition and Innovation Act of 2009 ("BPCIA''), a biosimilar applicant is required to provide the sponsor......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
